High-dose chemotherapy and stem cell support for breast cancer: where are we now?
作者： Renee M. Gerrero , Steven Stein , Edward A. Stadtmauer
DOI: 10.2165/00002512-200219070-00001
关键词:
摘要: To date, there is no definitive evidence that high-dose chemotherapy and haematopoietic stem cell support offers a survival advantage over conventional-dose for metastatic or high-risk primary breast cancer. Studies of disease discussed in this review have an adequate duration follow-up given the short natural history Thus, results these studies are unlikely to change with longer observation period. On other hand, treatment cancer need light type disease. Results unpublished available may still demonstrate patients We continue encourage participation innovative clinical studies.
springer.com
sci-hub.se 参考文章(32)
Gisselbrecht C, Delain M, Herbrecht R, Lepage E, Guillevin L, Maraninchi D, Lotz Jp, Janvier M, Devaux Y, Bremond D, Extra Jm, Peny Am, Cyclophosphamide/mitoxantrone/melphalan (CMA) regimen prior to autologous bone marrow transplantation (ABMT) in metastatic breast cancer. Bone Marrow Transplantation. ,vol. 18, pp. 857- 863 ,(1996)
J. Winter, R. S. Weiner, R. Gray, N. Ciobanu, H. M. Lazarus, Phase I trial of high-dose melphalan, high-dose etoposide and autologous bone marrow re-infusion in solid tumors: an Eastern Cooperative Oncology Group (ECOG) study. Bone Marrow Transplantation. ,vol. 14, pp. 443- 448 ,(1994)
Nicholas Thatcher, Michael Lind, Carboplatin in small cell lung cancer. Seminars in Oncology. ,vol. 17, pp. 40- 48 ,(1990) , 10.5555/URI:PII:009377549090071A
K Antman, L Ayash, A Elias, C Wheeler, M Hunt, J P Eder, B A Teicher, J Critchlow, J Bibbo, L E Schnipper, A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy. Journal of Clinical Oncology. ,vol. 10, pp. 102- 110 ,(1992) , 10.1200/JCO.1992.10.1.102
S F Williams, R Mick, R Desser, J Golick, J Beschorner, J D Bitran, High-dose consolidation therapy with autologous stem cell rescue in stage IV breast cancer Journal of Clinical Oncology. ,vol. 7, pp. 1824- 1830 ,(1989) , 10.1200/JCO.1989.7.12.1824
K K Fields, G J Elfenbein, H M Lazarus, B W Cooper, J B Perkins, R J Creger, O F Ballester, J H Hiemenz, W E Janssen, P E Zorsky, Maximum-tolerated doses of ifosfamide, carboplatin, and etoposide given over 6 days followed by autologous stem-cell rescue: toxicity profile. Journal of Clinical Oncology. ,vol. 13, pp. 323- 332 ,(1995) , 10.1200/JCO.1995.13.2.323
W R Bezwoda, L Seymour, R D Dansey, High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial. Journal of Clinical Oncology. ,vol. 13, pp. 2483- 2489 ,(1995) , 10.1200/JCO.1995.13.10.2483
William P Peters, M Ross, JJ Vredenburgh, Barry Meisenberg, LB Marks, E Winer, J Kurtzberg, RC Bast Jr, R Jones, E Shpall, K Wu, G Rosner, C Gilbert, B Mathias, None, High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. Journal of Clinical Oncology. ,vol. 11, pp. 1132- 1143 ,(1993) , 10.1200/JCO.1993.11.6.1132
Joseph A. Sparano, Ping Hu, Radha M. Rao, Carla I. Falkson, Antonio C. Wolff, William C. Wood, Phase II Trial of Doxorubicin and Paclitaxel Plus Granulocyte Colony-Stimulating Factor in Metastatic Breast Cancer: An Eastern Cooperative Oncology Group Study Journal of Clinical Oncology. ,vol. 17, pp. 3828- 3834 ,(1999) , 10.1200/JCO.1999.17.12.3828
B Fisher, S Anderson, D L Wickerham, A DeCillis, N Dimitrov, E Mamounas, N Wolmark, R Pugh, J N Atkins, F J Meyers, N Abramson, J Wolter, R S Bornstein, L Levy, E H Romond, V Caggiano, M Grimaldi, P Jochimsen, P Deckers, Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22. Journal of Clinical Oncology. ,vol. 15, pp. 1858- 1869 ,(1997) , 10.1200/JCO.1997.15.5.1858